- Previous Close
0.1325 - Open
0.1325 - Bid 0.0936 x --
- Ask 0.1504 x --
- Day's Range
0.1325 - 0.1325 - 52 Week Range
0.0100 - 0.1713 - Volume
4,500 - Avg. Volume
108 - Market Cap (intraday)
23.152M - Beta (5Y Monthly) 1.36
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0000 - Earnings Date Apr 7, 2025 - Apr 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy; and in phase 2/3 clinical trial for Radiodermatitis associated to radiotherapy, as well as in phase 2a clinical trial for ulcerative colitis. The company also develops Pantoprazole Magnesium for the treatment of gastric reflux; Cleo-35 for the treatment of hormonal acne in women; Dexlansoprazole; R-Spinasome anti-aging cream, serum, and regenerating creams; and anti-aging products, including day, night, and eye creams under the Purgenesis name. Devonian Health Group Inc. is headquartered in Québec, Canada.
groupedevonian.comRecent News: DVHGF
View MorePerformance Overview: DVHGF
Trailing total returns as of 4/7/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DVHGF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DVHGF
View MoreValuation Measures
Market Cap
21.31M
Enterprise Value
14.14M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.35
Price/Book (mrq)
2.09
Enterprise Value/Revenue
0.90
Enterprise Value/EBITDA
143.40
Financial Highlights
Profitability and Income Statement
Profit Margin
-3.86%
Return on Assets (ttm)
-1.29%
Return on Equity (ttm)
-6.07%
Revenue (ttm)
22.39M
Net Income Avi to Common (ttm)
-864.74k
Diluted EPS (ttm)
-0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
12.45M
Total Debt/Equity (mrq)
15.67%
Levered Free Cash Flow (ttm)
9.11M